The NexTGen team is supported through the Cancer Grand Challenges initiative. Learn more here

Our Team

 

“What excites me most  is the energised, passionate group of people we’ve brought together -including world-renowned scientist and rising stars who will become the future leaders in childhood oncology. That’s where out-of-the-box thinking comes from – suddenly, you find you’re learning from each other and working out how you can use each other’s special expertise to tackle a complex problem.”

Professor Catherine Bollard, Children’s National Hospital, USA.

;

Our Team

 

“What excites me most  is the energised, passionate group of people we’ve brought together -including world-renowned scientist and rising stars who will become the future leaders in childhood oncology. That’s where out-of-the-box thinking comes from – suddenly, you find you’re learning from each other and working out how you can use each other’s special expertise to tackle a complex problem.”

Professor Catherine Bollard, Children’s National Hospital, USA.

;

About us

The team, co-led by Professor Catherine Bollard (Children’s National Hospital, USA) and Dr Martin Pule (University College London, UK) brings together a multidisciplinary international group of UK, US and French CAR T-cell experts and scientists.  The team consists of experts from highly diverse displines including oncology, hematology, immunology, transplantation/cell therapy, glycobiology, proteomics, biostatistics, mathematics and artificial intelligence. The team has extensive know-how translating scientific discoveries to the clinic. Also, embedded within the team are a group of patient advocates bringing the patient/parent perspective to the forefront of the challenge.

The team will develop a genetic engineering ‘tool kit’ designed specifically for children’s solid tumours. This tool kit will be used to engineer T-cells in more advanced ways to overcome the barriers that solid cancers put in their way. 

Program Overview

Our central hypothesis is that by coupling deep knowledge of childhood cancer development with advanced cellular engineering technologies along with progressive clinical development will be the fastest route to producing effective cellular therapies for high-risk paediatric solid tumours.

NexTGen combines detailed studies of primary tumours to discover new targets and understand how the tumour microenvironment (TME) destabilises T-cell function. This, along with a closely coupled clinical development programme will guide the progressive engineering of T-cells to result in transformative therapies. 

Meet the team

Loading...
NexTGen